These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 36598161)
21. Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. Ferrazzi P; Spirito P; Iacovoni A; Calabrese A; Migliorati K; Simon C; Pentiricci S; Poggio D; Grillo M; Amigoni P; Iascone M; Mortara A; Maron BJ; Senni M; Bruzzi P J Am Coll Cardiol; 2015 Oct; 66(15):1687-96. PubMed ID: 26449139 [TBL] [Abstract][Full Text] [Related]
22. Revelation of an obstructive hypertrophic cardiomyopathy in an elderly patient. Patanè S; Marte F; Portaro A Int J Cardiol; 2010 Nov; 145(2):e41-e43. PubMed ID: 19181403 [TBL] [Abstract][Full Text] [Related]
23. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten. Mathai S; Williams L Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022 [TBL] [Abstract][Full Text] [Related]
24. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics. Lafitte S; Reant P; Touche C; Pillois X; Dijos M; Arsac F; Peyrou J; Montaudon M; Ritter P; Roudaut R; Demaria A J Am Coll Cardiol; 2013 Aug; 62(9):842-50. PubMed ID: 23810875 [TBL] [Abstract][Full Text] [Related]
25. From 100 to 0: Endocardial Radiofrequency Ablation of Septal Hypertrophy for Management of Hypertrophic Cardiomyopathy. Peigh G; Wasserlauf J; Choudhury L; Knight BP; Kim S JACC Case Rep; 2020 Jul; 2(8):1173-1177. PubMed ID: 34317442 [TBL] [Abstract][Full Text] [Related]
26. Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy. Albano BB; Fadreguilan EC; Chua JM; Ho J; Medrano AB Cardiol Res; 2017 Feb; 8(1):20-25. PubMed ID: 28275421 [TBL] [Abstract][Full Text] [Related]
27. Time to significant gradient reduction following septal balloon occlusion predicts the magnitude of final gradient response during alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Almasood A; Garceau P; Woo A; Rakowski H; Schwartz L; Overgaard CB JACC Cardiovasc Interv; 2011 Sep; 4(9):1030-4. PubMed ID: 21939945 [TBL] [Abstract][Full Text] [Related]
28. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Philipson DJ; DePasquale EC; Yang EH; Baas AS Heart Fail Rev; 2017 Nov; 22(6):879-888. PubMed ID: 28856513 [TBL] [Abstract][Full Text] [Related]
32. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy. Habib M; Hoss S; Bruchal-Garbicz B; Chan RH; Rakowski H; Williams L; Adler A Int J Cardiol; 2019 Dec; 297():75-82. PubMed ID: 31615649 [TBL] [Abstract][Full Text] [Related]
33. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score-matched cohort. Nguyen A; Schaff HV; Hang D; Nishimura RA; Geske JB; Dearani JA; Lahr BD; Ommen SR J Thorac Cardiovasc Surg; 2019 Jan; 157(1):306-315.e3. PubMed ID: 30279000 [TBL] [Abstract][Full Text] [Related]
34. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy. Dalo JD; Weisman ND; White CM Ann Pharmacother; 2023 Apr; 57(4):489-502. PubMed ID: 35950315 [TBL] [Abstract][Full Text] [Related]
35. Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. Deb SJ; Schaff HV; Dearani JA; Nishimura RA; Ommen SR Ann Thorac Surg; 2004 Dec; 78(6):2118-22. PubMed ID: 15561048 [TBL] [Abstract][Full Text] [Related]
36. Left ventricular remodeling following septal myectomy in hypertrophic obstructive cardiomyopathy. Yamabe T; Ginns J; Vedula V; Leb JS; Shimada YJ; Weiner SD; Takayama H JTCVS Open; 2022 Sep; 11():105-115. PubMed ID: 36172435 [TBL] [Abstract][Full Text] [Related]
37. THE PLACE OF CARDIAC COMPUTED TOMOGRAPHY IN PREOPERATIVE PLANNING OF EXTENDED SEPTAL MYECTOMY IN PATIENTS WITH OBSTRUCTIVE FORM OF HYPERTROPHIC CARDIOMYOMATHY. Tregubova MO; Rudenko KB; Lazoryshynets VV; Fedkiv SV; Trembovetskaya OM; Danchenko PA; Vitkovsky YI; Ishchenko MS; Gavrylyshyn AY; Parfentyeva VV; Stukov YY Probl Radiac Med Radiobiol; 2020 Dec; 25():592-606. PubMed ID: 33361864 [TBL] [Abstract][Full Text] [Related]
38. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620 [TBL] [Abstract][Full Text] [Related]
39. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Kotkar KD; Said SM; Dearani JA; Schaff HV Ann Cardiothorac Surg; 2017 Jul; 6(4):329-336. PubMed ID: 28944173 [TBL] [Abstract][Full Text] [Related]